Ayala Pharmaceuticals (NASDAQ:ADXS) Coverage Initiated at StockNews.com

Research analysts at StockNews.com started coverage on shares of Ayala Pharmaceuticals (NASDAQ:ADXS) in a research report issued to clients and investors on Sunday. The brokerage set a “sell” rating on the stock.

Ayala Pharmaceuticals Stock Performance

Shares of NASDAQ ADXS opened at $0.03 on Friday. The firm has a fifty day simple moving average of $0.03 and a two-hundred day simple moving average of $0.04. Ayala Pharmaceuticals has a 12 month low of $0.00 and a 12 month high of $0.97. The firm has a market capitalization of $1.28 million, a PE ratio of 0.00 and a beta of 1.63.

Ayala Pharmaceuticals Company Profile

Ayala Pharmaceuticals, Inc, a clinical-stage oncology company, primarily focuses on developing and commercializing small molecule therapeutics for people living with rare tumors and aggressive cancers. The company's lead candidates under development include AL102, an oral gamma secretase inhibitor for desmoid tumors; and aspacytarabine (BST-236), a novel proprietary anti-metabolite for first line treatment in unfit acute myeloid leukemia.